Imaging with [18f]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab.
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2013
At a glance
- Drugs Cetuximab (Primary) ; Everolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 24 Sep 2013 Results published in Cancer.
- 05 Jun 2007 Results have been published.
- 05 Jun 2007 Status changed from in progress to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History